Metabolites

Class imbalance remains a challenge in metabolomics research, where biological and technical variability can affect statistical inference and machine learning (ML) performance. Class-balancing algorithms address this issue by either increasing minority-class observations or reducing the number of majority-class samples. This study evaluated the impact of oversampling and undersampling algorithms on targeted and untargeted metabolomics datasets derived from LC-MS and GC-MS analyses of plasma samples from patients with glioblastoma, meningioma, and controls. Synthetic Minority Oversampling Technique (SMOTE) and Random Undersampling (RUS) were applied to balance the datasets, and their effects on data distribution, inter-feature correlations, and machine learning model performance were compared. RUS preserved the original feature distributions but reduced representativeness by removing the majority-class samples. In contrast, SMOTE introduced synthetic samples that altered covariance structures, increasing the risk of overfitting, particularly in small datasets (n=10). These effects diminished with larger groups (n=30), partially restoring correlations between metabolites. Model performance varied across the class-balancing algorithms. Random Forest classifiers benefited from both balancing methods, with undersampling often yielding higher F1 scores, whereas Support Vector Machine models showed reduced classification performance. These findings highlight the importance of selecting class-balancing strategies based on dataset size, analytical platform, and ML algorithm in metabolomics studies.

Background: Early detection of pancreatic ductal adenocarcinoma (PDAC) is critical. While faecal elastase-1 (FE-1) is a standard clinical marker for pancreatic function, its diagnostic accuracy for malignancy is limited. We sought to identify plasma metabolites that enhance FE-1 performance in symptomatic "at-risk" patients. Methods: Using the DEPEND cohort (CRUK C45617/A29908), plasma metabolomics was performed on patients with resectable PDAC (n=23) and healthy volunteers (n=24). Predictive modelling included feature selection and cross-validation, with further validation in an independent external cohort. Results: Citrulline was identified as significantly depleted in PDAC patients across discovery and validation cohorts. In isolation, Citrulline achieved an AUC of 0.86 (internal) and 0.88 (external validation). Standalone FE-1 demonstrated an AUC of 0.67. However, combining Citrulline and FE-1 significantly improved diagnostic performance, achieving a combined AUC of 0.96. Stratification revealed distinct metabolomic signatures associated with poorly differentiated tumours, suggesting a link to histological grade. Conclusions: Integrating Citrulline with FE-1 testing substantially improves PDAC detection in symptomatic patients. This non-invasive panel offers high diagnostic potential, though prospective validation is required to establish clinical cut-offs for routine practice.

Background/ObjectivesMetabolism-level interpretation of metabolomics datasets requires aggregation analyses across metabolites. One highlyused aggregation analysis is pathway enrichment analysis (PEA), which involves detecting pathways enriched with metabolites that are differential between experimental groups. Annotating metabolites with pathway associations is a prerequisite for PEA. While several knowledgebases define pathways and include metabolite-pathway annotations, these definitions are often partially or even grossly incomplete due to limitations in current metabolic knowledge and its curation, which greatly limits the effectiveness of PEA. MethodsIn this work, we used a novel multitask classification, graph convolutional-like neural network to generate high-quality metabolite-pathway annotations for pathways defined across KEGG, MetaCyc, and Reactome. We then included these predicted metabolite-pathway annotations when performing PEA on 990 datasets deposited in Metabolomics Workbench. ResultsWe demonstrate an 8-fold increase in the median number of enriched pathways detected across these datasets compared to using only knowledgebase-derived annotations. ConclusionsThe significant increase in enriched pathways substantially improves the biological and biomedical interpretability of metabolomics datasets.

Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy posing significant diagnostic challenges, particularly in distinguishing it from other adrenal tumors, such as adenoma and pheochromocytoma, due to overlapping imaging and biochemical features. Improved non-invasive tools are critically needed for earlier, more accurate classification of this rare cancer. This pilot study analyzed serum lipidomic profiles in ACC, pheochromocytoma, and adenoma patients versus healthy volunteers. The most significant alterations occurred in sphingomyelins (SM) and diacylglycerols (DG). All tumor samples showed reduced very-long odd-chain SM (e.g., SM 39:1, SM 41:1, SM 41:2) and elevated DG (e.g., DG 34:1, DG 34:2, DG 36:2). These abnormalities were most pronounced in malignant tumors: ACC and metastases (AUC = 0.933), followed by pheochromocytoma (AUC = 0.800) and adenoma (AUC = 0.711). ACC patients also exhibited specific lipid signatures with decreased alkyl/alkenyl phospholipids (e.g., PE O-38:5) and lysophosphatidylcholines (e.g., LPC 20:5, LPC 18:2) versus healthy volunteers, not observed in pheochromocytoma or adenomas. Ceramide species (e.g., Cer 42:2;O2, Cer 34:1;O2) were increased in ACC compared to the other tumor types. Incorporating lipid-to-lipid ratios (Cer/SM, Cer/DG) further improved statistical model accuracy. Compared to clinical biochemistry/oxidative stress (OS) parameters, lipidomic profiling showed superior discriminatory power in adrenal tumor diagnosis. The presented study shows the serum lipidomic profiling as a promising non-invasive method for distinguishing adrenal tumor subtypes (ACC, pheochromocytoma, and adenoma) from healthy individuals, with strong diagnostic potential for ACC.

Mass Spectrometry Metabolomics Identification Connection Algorithm (MSMICA) is an algorithm for automated metabolite identification in untargeted liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analyses. Limitations in metabolite identification can occur due to the availability and cost of standards and prevent recognition of metabolic factors impacting human health and disease. MSMICA performs mass-to-charge-ratio matching with chemical structures and clusters of LC-HRMS features for adduct and isotope forms. A local optimization is then used to integrate retention time prediction, metabolite precursor-product and transporter correlations, and biospecimen-specific abundance information for metabolite identification. Applying MSMICA to various internal and external mammalian datasets, validation results showed a 96.2 +- 5.1% correct rate of metabolite identification. When multiple LC-HRMS datasets were used, MSMICA enabled greater metabolite identifications, expanded metabolic pathway coverage, and data harmonization. Thus, MSMICA applies multiple pieces of evidence to substantially improve metabolite identification coverage and accuracy for known metabolites.

Untargeted LC-MS metabolomics datasets often contain large numbers of redundant and non-informative features arising from background contaminants, multiple ion forms, poorly integrated peaks, and other low-quality signals. These features complicate downstream analysis by inflating feature space, degrading molecular networks, impeding pathway analysis, and obscuring statistically meaningful changes. Here, we present MetaboCensoR, an input-versatile Shiny application and local R package for analyte-centric peak table filtering. The workflow integrates four complementary modules for blank filtering, redundant ion-species filtering, quality-control filtering, and peak-based filtering. MetaboCensoR also provides interactive threshold optimization, exportable annotation tables, and synchronized filtering of associated .mgf files. The approach was evaluated across three independent datasets covering plant extracts, human cell lines, and bacterial interactions. Across these case studies, data filtering reduced feature redundancy and improved downstream interpretation in feature-based molecular networking, pathway-level functional analysis, and differential abundance testing, while preserving known target metabolites. These results show that systematic peak table filtering can substantially improve the interpretability and analytical value of untargeted metabolomics data.

Glaucoma is an irreversible blinding disease that affects millions of individuals worldwide. Elevated intraocular pressure (IOP), regulated by the trabecular meshwork (TM) in the anterior eye, is the only modifiable risk factor. Human TM cells can be cultured from donor eyes, providing a precious resource for studying factors that induce or prevent glaucoma. The goal of this study was to produce datasets that define the molecular profile of human non-glaucomatous TM cells. Using 18 human TM cell strains cultured from non-glaucomatous individuals deposited from seven laboratories in the USA and UK, this study used transcriptomic, proteomic, lipidomic, and metabolomic analyses to characterize the molecular content of TM cells. The data herein provides the most comprehensive multiomic analyses of human TM cells to date and will be a useful resource for researchers and clinicians in the TM and glaucoma fields.

Background. Plasma and serum metabolomic studies of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) have repeatedly implicated hypometabolic, lipid, mitochondrial, redox and tryptophan-kynurenine pathways, but prior cohorts have been modest in size and have used heterogeneous case definitions. Whether similar pathway-level signals are detectable at scale in dried blood spots (DBS), across questionnaire-derived fatigue constructs and across orthogonal LC gradients in the same individuals remains unresolved. Methods. We profiled DBS extracts from 1,784 community-cohort adults by reverse-phase LC-MS using paired 5 min and 15 min gradients. Six questionnaire-derived endpoints captured a pragmatic self-reported PEM-like phenotype, a DSQ-derived PEM-like construct, high or review clinical status, temporal fatigue state, comorbid fatigue and self-reported chronic fatigue. The locked primary endpoint for Phase 1 was pragmatic_fatigue_pem with 226 cases and 914 controls after excluding major metabolic comorbidity. We tested a biology-first panel comprising 22 literature-curated metabolites represented by four participant-level descriptors each, and evaluated three discovery extensions: a targeted m/z search of additional literature candidates, a hypothesis-free univariate screen across 4,553 5 min and 5,625 15 min consensus features, and pairwise z-difference ratios. Endpoint-specific Ridge classifiers were evaluated by five-fold out-of-fold AUC with bootstrap stability filtering. Cross-gradient agreement was assessed by per-metabolite AUC concordance between paired 5 min and 15 min profiles. Severity was modelled as an ordinal grade derived from the number of fatigue criteria met and chronic-fatigue-form status. Results. The biology-first DBS panel achieved out-of-fold AUC 0.81 for the pragmatic self-reported PEM-like endpoint (226 cases / 914 controls). The DSQ-derived PEM-like construct reached AUC 0.60 (57 cases / 201 controls) on the un-filtered set and AUC 0.778 (SD 0.013, twenty seeds) in a post-hoc signature-decomposition follow-up restricted to participants without a self-declared major-metabolic-history tag (29 cases / 230 controls); both are treated as construct-validity anchors rather than as provoked or clinically adjudicated PEM. An optimised operationalisation of the same construct (panel-self normalisation, restriction to non-comorbid participants and demographic covariates) reached AUC 0.71 (95 % CI 0.55 to 0.76), and an exploratory age-stratified signature decomposition suggested age-dependent pathway composition that requires confirmation given small per-stratum case counts. Stable contributors mapped to carnitine-shuttle, TCA-cycle, redox-thiol and tryptophan-kynurenine pathways. Cross-gradient analysis of 22 matched metabolites yielded Pearson r = 0.62 for signed univariate effects (p = 0.002; 68 % directional agreement). The metabolomic score increased with severity grade (Spearman rho = 0.45, p = 4 x 10^-91; median scores 0.24, 0.51 and 0.75 across grades 0, 1 and 2). Sensitivity analyses on the covariate-complete subset (n = 565; 138 cases / 427 controls) showed that the DBS signal was robust to adjustment for age, sex, BMI and medication burden (DBS-only AUC 0.76, DBS plus covariates 0.78, covariates only 0.64), and produced a metabolomic-specific lift of approximately 0.13 AUC over the strongest anti-leak declarative cross-form questionnaire baseline (AUC 0.63). DBS-only AUC was stable across sex, age and BMI subgroups, and a 1:4 nearest-neighbour matched analysis on age, sex and BMI yielded AUC 0.72 (95 % CI 0.67 to 0.77). The observed pattern supported pathway-level convergence with prior ME/CFS metabolomics literature, including carnitine shuttle, fatty-acid beta-oxidation, TCA cycle, redox-thiol, urea cycle, glycerophospholipid and tryptophan-kynurenine axes. In contrast, the hypothesis-free 15 min screen produced high-AUC features that mapped predominantly to environmental or technical signals, including pesticide, industrial-amine and mobile-phase artifact annotations; only one of eight top leads, a truncated oxidised phospholipid, was biologically plausible, and none had tandem-MS support. Conclusions. In this large community cohort, a literature-curated DBS metabolomic panel captured pathway-level biology associated with a questionnaire-derived PEM-like fatigue phenotype, showed directional concordance across LC gradients, scaled with symptom severity and remained robust to key demographic, anthropometric and anti-leak questionnaire baselines. The findings converge with several metabolic axes previously reported in ME/CFS plasma and serum studies, including carnitine-shuttle, TCA-cycle, redox-thiol, urea-cycle, glycerophospholipid and tryptophan-kynurenine pathways. They should not be interpreted as clinical validation of a diagnostic test, screening tool or objective provoked-PEM biomarker. Rather, they support at-home-compatible DBS metabolomics as a biologically grounded platform for future clinically adjudicated validation, decision-support development and longitudinal monitoring in fatigue and PEM-like syndromes. Because DBS contains cellular and plasma-derived components, matrix effects must be considered when comparing individual metabolites with venous plasma or serum studies, and hypothesis-free screening at this scale can preferentially surface exposome or technical variance unless molecular identification is enforced before biological interpretation.

Endometriosis, a common inflammatory gynecological disorder affecting up to 10% of women worldwide, is characterized by the presence of endometrium-like tissue outside the uterus. Current diagnostic methods, such as ultrasound and MRI, effectively detect ovarian and deep endometriosis but fail to detect more common peritoneal type. Diagnosing peritoneal endometriosis currently necessitates invasive laparoscopy and histological confirmation. Despite numerous efforts, no new reliable biomarkers have successfully transitioned into routine clinical use. This study aimed to investigate the use of targeted metabolomics to discover metabolite ratios capable of identifying endometriosis in plasma samples. We analyzed a discovery population of 235 patients and a validation population of 278 patients. All cases and controls in both populations were diagnosed by laparoscopy. Control subjects included individuals presenting with symptoms such as pain, dysmenorrhea, infertility, or other benign conditions, but who had no laparoscopic evidence of endometriosis. Using generalized linear models (GLMs) and machine learning, the study identified specific metabolite ratios as potential biomarkers that can distinguish different types of endometriosis and enable mass spectrometry-based diagnostics for peritoneal endometriosis. The best-validated GLM, derived from the concentration ratios of amino acids, acylcarnitines, sphingomyelins, and phosphatidylcholines, consisted of Thr/SM(OH) C22:2 + PC aa C40:5/SFA_PC + lysoPC a C16:0/SM(OH) C16:1. This model yielded an AUC of 0.82 (95% CI 0.619-0.891, with 76% sensitivity and 81% specificity) for peritoneal endometriosis. This innovative approach offers a robust diagnostic model, addressing an unmet medical need by facilitating earlier detection of peritoneal endometriosis and improving overall clinical management.

The limited understanding of transporter substrate spectra constrains our ability to interpret cell and membrane function, highlighting the need for methods that enable transporter deorphanization and characterization of promiscuous transport activities. Here, we present a Xenopus oocyte-based platform for unbiased transporter substrate discovery. Oocytes expressing heterologous solute carrier proteins (SLC) were incubated in human blood serum, a chemically complex metabolite library containing thousands of endogenous metabolites and xenobiotics, followed by paired untargeted LC-MS/MS profiling of intracellular extracts and surrounding medium to capture metabolite exchange events. Across the five human SLC transporters, viz. SLC10A2, SLC10A6, SLC13A2, SLC16A10, and SLC46A1, metabolite exchange signatures were detected, and automated feature annotation was refined by manual chromatographic peak inspection. The workflow recovered known substrates of SLC10A2 and SLC16A10 and identified additional transported metabolites with MS/MS confirmation. This method provides a scalable framework for transporter substrate profiling and prioritization of candidates for targeted validation.

Background Besides hyperglycemia, type 2 diabetes (T2D) is characterized by dyslipidemia, which is typically assessed using traditional clinical lipid measurements. However, molecular plasma lipids beyond these traditional markers can provide additional information about an individuals health status. For molecular lipids to be used effectively, certain characteristics, such as their temporal variability, need to be determined. Methods We analyzed the plasma lipidome for three consecutive time points, each three months apart, of 51 individuals with T2D using targeted liquid chromatography coupled to mass spectrometry (LC-MS). 513 lipid species across 25 (sub)classes were quantified by this approach and the temporal variability were calculated. Moreover, to identify sex differences in the plasma lipidome, we analyzed 914 samples of a cross-sectional T2D cohort with the same approach. Results Neutral lipids and phosphatidylserine had the highest temporal variability which was independent of their platform-specific variability. In contrast, glycosphingolipids were found to be relatively stable over time in individuals with T2D. Acyl-chain analysis revealed generally similar variability in the acyl-chain groups but indicated a higher temporal variability in medium-length acyl-chains. Lipid-sex association analysis showed markedly higher sphingomyelins, phosphatidylcholines, and phosphatidylethanolamines in women and higher acylcarnitines in men. Overall, approximately one-third of measured lipids showed significant sex differences independent of age, BMI, diabetes duration, glycemic control, and medication use. Conclusions Our findings provide insights into temporal variability of molecular lipids. This variability should be considered when assessing novel lipid biomarkers. Likewise, sex differences in these lipids need to be considered in precision medicine for diabetes management.

Isotopic Metabolic Flux Analysis (I-MFA) is a standard approach for estimating intracellular metabolic fluxes. I-MFA infers fluxes by comparing simulated and measured metabolite isotopologue distributions (MIDs) of metabolites from isotope labeling experiments. MIDs represent fractional abundances that strictly sum to one for any given metabolite, thus they are inherently compositional data. However, state-of-the-art estimation approaches rely on calculating standard Euclidean distances between MIDs in a non-compositional paradigm, introducing a systemic bias. To resolve this, our study proposes compositional I-MFA. We demonstrate how to construct a meaningful orthonormal basis for MIDs via ordered sequential binary partitioning, which can be used to perform isometric log-ratio (ILR) transformation. As a minimal change to existing I-MFA workflows, we suggest estimating fluxes by minimizing Euclidean distances between ILR-transformed MIDs. We validated this framework against traditional methods using both a toy model and a biologically realistic model, evaluating point estimates, sensitivity across varied true fluxes, and confidence intervals. In the two examples, compositional I-MFA consistently outperformed traditional approaches, reducing mean squared error of flux point estimates by an average of 42.6% and substantially narrowing confidence intervals. We conclude that compositional data analysis significantly improves I-MFA and can be implemented as a simple drop-in replacement for current pipelines. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=156 SRC="FIGDIR/small/742769v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@1a53aa4org.highwire.dtl.DTLVardef@ad225aorg.highwire.dtl.DTLVardef@aa430eorg.highwire.dtl.DTLVardef@1880ca_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LINew compositional data approach improves metabolic flux estimation. C_LIO_LIThis data transformation requires minimal changes to existing workflows. C_LIO_LIThe new method reduced MSE of flux estimates by 42.6% in two examples tested. C_LIO_LIThe confidence intervals of the estimated fluxes were substantially narrowed. C_LIO_LIEstimation accuracy remained robust across a wide range of metabolic fluxes. C_LI

BACKGROUND: Erythrophagocytosis constitutes a major pathogenic mechanism of metabolic dysfunction associated fatty liver disease (MAFLD). Our previous research established a quantitative thin-layer chromatography (TLC) technique for sphingomyelin, revealing reduced levels in the red blood cells (erythrocytes) of patients with metabolic dysfunction associated fatty liver disease (MAFLD). This reduction was accompanied by erythrocyte sphingosine accumulation, a driver of pro-inflammatory erythrophagocytosis, though sphingosine 1-phosphate release remained stable. To better understand erythrocyte sphingosine metabolism, we adapted our quantitative TLC method to analyze sphingosine within the erythrocyte-conditioned media (ECM) of MAFLD patients. Methodology Separation was performed on 10X10cm Silica gel 60 F254 plates using a mobile phase of chloroform, methanol, acetic acid, and water (60:50:1:4 v/v/v/v). The dynamic range, linearity, and range of linearity were assessed by analysing sphingosine levels from 0.1 to 10microg/spot. We validated the system precision and sensitivity by performing triplicate analyses of sphingosine standards (1.25, 2.5, and microg). The limits of detection and quantification were derived from the calibration curve slope and standard deviation (3.3 XSD/slope for LOD; 10 XSD/slope for LOQ). Accuracy was assessed via recovery tests at 100%, 200%, and 300% of a 2.5microg load. We confirmed specificity by evaluating the retention factors against other lipid species. This protocol was applied to Folch-extracted lipids from the ECM (5 X 107 cells/ml) of four MAFLD patients and four healthy controls, spiked with 5microg of sphingosine. Findings The calibration model, based on combined Green and Blue color intensities, followed the linear equation y = -11.171x + 353.25(R2 = 0.94). Interday precision values were 0.21%, 1.65%, and 0.44%, while recovery rates (accuracy) ranged from 94.5% to 98.7%. The measured LOD and LOQ were 0.75microg and 1.21microg, respectively. The sensitivity was calculated at 90ng. Statistical analysis showed no significant variance in sphingosine concentrations in erythrocyte-conditioned media between the MAFLD group and the control group. Summary The described thin layer chromatography is accurate, precise, sensitive, with good limits of detection and quantification, and most importantly is low-cost and time-efficient. Using this method, we show that while erythrocytes of MAFLD patients exhibit sphingosine accumulation, the utilisation of exogenous sphingosine from their erythrocytes is not affected. This suggests that the metabolic shift may be driven by increased sphingosine supply from the plasma.

Background: The Dietary Inflammatory Index (DII) is widely used to assess the inflammatory potential of diet, but it relies on self-reported dietary assessment and does not directly capture individual differences in metabolism as an intermediate connection to inflammation. High-resolution metabolomics provides objective measurements that complement dietary assessment to support precision nutrition to control inflammation. Objective: We developed, tested, and applied a Dietary Metabolite Inflammatory Index (DMII) to assess diet-related chronic inflammation using metabolites measured by liquid chromatography high-resolution mass spectrometry. Methods: DII was calculated using dietaryindex R package with Block Food Frequency Questionnaire (FFQ) data. To develop the DMII, chronic inflammation-related dietary metabolites corresponding to the DII food parameters were found through a literature review. Dietary metabolites were identified and quantified by authentic standards by our established laboratory procedures. DMII uses the same inflammatory effect scores as the DII. Three DMII versions were developed: concentration-based, median-based, and quintile-based DMII. Mean and standard deviation of 29 dietary metabolites were calculated by using 3025 human plasma samples from 3 studies. DMII was tested in the Center for Health Discovery and Well-Being cohort (CHDWB) and the Atlanta African American Maternal and Child cohort (ATLAA) using chronic inflammation biomarkers, including high-sensitivity C-reactive protein (hsCRP), CRP, and IL6. The median-based DMII was further applied to four Alzheimers disease metabolomics datasets as a proof-of-concept application. Results: In the CHDWB study, concentration-based DMII had a weak positive correlation with Block FFQ-derived DII and strongly correlated with median-based and quintile-based DMII. In the same study, all three DMII versions had significant positive correlations with hsCRP and IL6. In the ATLAA study, only concentration-based DMII was positively associated with CRP and IL6. Higher median-based DMII was associated with higher odds of Alzheimers disease. Conclusions: DMII provides a metabolomics-based framework for assessing diet-related chronic inflammation using metabolomics data. This metabolomics approach may complement self-reported dietary assessment to use diet and nutrition to help protect against chronic disease linked to inflammation.

Comprehensive detection of steroids, beyond the limited panels typically analyzed in clinical chemistry laboratories, has become increasingly important given their pivotal roles in diverse biological processes. However, steroid quantification poses several analytical challenges, including differences in ionization efficiency and structural similarities across the entire steroid metabolic network. To address these challenges, we developed a targeted ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) assay to analyze 21 steroids using reverse-phase chromatography combined with rapid polarity switching. Mass spectrometry (MS) analysis was performed in scheduled multiple reaction monitoring (sMRM) mode. Depending on the steroid and matrix, the validated lower limits of quantitation (LLOQ) ranged from 12.0 pM to 1216 pM in plasma and 41.1 pM to 384 pM in fecal sample homogenates. In adipose tissue, it was from 0.01 pmol/g to 9 pmol/g. Measured steroid concentrations obtained from the commercial control samples (MassTrak Steroid Serum QC Set 1 and the MassCheck Steroid Panel 1 Serum Control) showed close agreement with the reference values. As a proof of concept, the method was successfully applied to 469 plasma samples in several projects, 15 adipose tissue samples, and 332 fecal samples, demonstrating its applicability to large-scale studies. In conclusion, the method enables sensitive, derivatization-free quantification of an expanded steroid panel in plasma and complex biological matrices, including adipose tissue and fecal samples, representing a significant advancement in comprehensive steroid profiling.

Metabolomics studies are increasingly being applied with hundreds to thousands, even tens of thousands of samples that demand rapid, automated data processing while maintaining analytical sensitivity or quantitative accuracy. A major computational bottleneck is feature finding, which is the transformation of LC-MS and LC-MS/MS data into a set of analyte signals aligned and quantified across samples. Feature finding can be computationally intensive and often requires manual iterative parameter optimization. To accelerate this process, we present the Everything Bagel (EB) feature finder, an ultra-fast automated feature finding tool that integrates feature detection, retention-time alignment, and gap filling designed for run-time and memory efficiency. We benchmarked EB against two automated feature finding methods on eight benchmarking datasets. Specifically, we evaluated these three feature finding methods by measuring spike-in standard detection coverage, dilution series quantification accuracy, and yeast 12C/13C credentialed features. In this evaluation, the EB feature finder achieved performance comparable to, and often exceeding, existing methods while requiring up to 150-fold lower CPU hours and up to 113-fold lower wall time. We further demonstrated the bioanalytical validity of EB by reanalyzing published datasets used for biomarker discovery and reproduced biologically significant features that matched the published findings using manually tuned feature finding settings. Taken along with the speed improvements, we anticipate EB will enhance the ability to automatically analyze datasets with thousands to tens of thousands of samples for the community.

Introduction: Lipids are considered both drivers and biomarkers of cardiometabolic diseases. As glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for diabetes and obesity management, it is crucial to understand how they affect the related comorbidities through the circulating lipidome. This study investigated the lipidomic changes induced by liraglutide treatment when compared to placebo in people with type 2 diabetes (T2D) to characterise lipid remodelling and its association with clinical outcomes. Research design and methods: This post-hoc study analysed plasma samples using liquid chromatography-mass spectrometry (LC-MS/MS) from LIRAFLAME, a randomised, double-blind, placebo-controlled, parallel-group trial. A hundred people with T2D received up to 1.8 mg of liraglutide or placebo once daily for 26 weeks. Plasma samples were collected at baseline, week 13 and week 26. Results: Liraglutide treatment resulted in a statistically significant increase in multiple lysophospholipid subclasses, including LPCs, LPC(O)s, LPC(P)s, LPEs, and LPE(P)s, observed at 13 weeks and sustained at 26 weeks compared to placebo. These increases were not mediated by the change in BMI. Triglyceride concentrations decreased at 13 weeks, while fatty acid levels declined at 26 weeks, consistent with enhanced lipid remodelling. The increase in LPC(O)s was associated with favourable decreases in ALAT, MCP-1, and UACR, suggesting anti-inflammatory effects with hepatic, renal, and cardiovascular benefits. Conclusions: Compared to placebo, 26 weeks of liraglutide treatment resulted in a favourable lipidomic shift from a triglyceride-rich profile towards one enriched in lysophospholipids. This lipid remodelling was associated with improvements in hepatic, renal, and inflammatory markers.

High dietary fructose consumption is a major contributor to the development of obesity and related cardiometabolic diseases, highlighting the need for accurate assessment of fructose metabolism in humans. Stable isotope tracer approaches, such as 13C6-fructose, require highly sensitive and specific analytical methods to quantify both concentrations and isotopic enrichments. In this study, we developed and validated a robust gas chromatography-triple quadrupole mass spectrometry (GC-QQQ)-based method for the simultaneous measurement of unlabeled and 13C6-fructose in human plasma. The method employs oximation and per-acetate derivatization, and demonstrates high specificity and accuracy. Intra- and inter-assay precision were below 10%, with no detectable carry-over, and a lower limit of quantification (LLOQ) of 0.1 nmol/mL for concentration and 0.02 molar percent excess (MPE%) for enrichment and no interference from glucose. We further compared data acquisition using multiple reaction monitoring (MRM) and selected ion monitoring (SIM). MRM showed superior performance at the low concentrations and enrichment levels characteristic of clinical plasma samples, resulting in improved sensitivity and lower LLOQs compared to SIM. Overall, this validated method provides a sensitive and reliable approach for fructose tracer studies in humans. Its application will facilitate robust investigations into fructose metabolism, and its role in metabolic dysregulation and obesity-related disease.

LC/MS-based food lipidomics provides detailed information on intact lipid species, but the resulting datasets are often difficult to translate into concepts directly useful for food quality, processing, nutritional profiling and authenticity assessment. Here, we present Lipid Food Profile (LFP), a module of the LipidOne platform designed to convert annotated LC/MS lipidomics data into interpretable food-relevant lipid indices. LFP applies an in silico hydrolysis strategy to reconstruct acyl, alkyl and alkenyl chains from intact lipid species while preserving their lipid-class origin. The reconstructed information is then summarized into index categories related to food lipid quality, compositional balance, omega balance, oxidative stability, chain remodelling and ether-linked chain contribution. The interpretative value of LFP was evaluated using three published food lipidomics datasets addressing different analytical questions: X-ray-induced lipid remodelling in Chlorella vulgaris, spatial lipid heterogeneity in Mugil cephalus bottarga, and geographical-origin assessment of camel milk. Across these case studies, LFP recovered the main conclusions of the original lipidomics investigations, including treatment-associated lipid remodelling, inner-outer layer differences in bottarga and regional variation in camel milk. Importantly, LFP reorganized these findings into a smaller number of food-oriented indices, providing additional information on saturation balance, oxidative susceptibility, chain architecture and classification potential. Overall, LFP provides an interpretative layer for LC/MS food lipidomics that complement conventional fatty-acid analysis and molecular-species-based interpretation. By translating complex lipidomic tables into structured lipid index profiles, the module may support more accessible and chemically meaningful analysis of food composition, processing effects, lipid quality and exploratory traceability applications. LFP is freely accessible through the LipidOne web platform (LipidOne.eu). HighlightsO_LILipid Food Profile translates LC/MS food lipidomics into interpretable lipid indices. C_LIO_LIThe workflow preserves chain and lipid-class information without chemical hydrolysis. C_LIO_LIPublished case studies show that LFP recovers and extends previous interpretations. C_LIO_LILFP supports food quality, processing and exploratory origin/authenticity assessment. C_LIO_LIThe module complements conventional fatty-acid analysis and molecular lipidomics. C_LI

External biological knowledge provides valuable information about relationships among metabolites, yet this information is usually not incorporated directly into statistical estimation procedures. Most existing approaches estimate metabolite effects independently, ignoring known biochemical structure such as shared subclasses and pathway membership. We propose a Bayesian hierarchical framework that improves metabolite effect estimates by incorporating external biological information describing relationships among metabolites. The proposed method improves metabolite-specific estimates by allowing related metabolites to borrow information from one another while preserving metabolite-level inference. We evaluate the methodology using simulation studies across a range of sample sizes and heterogeneity regimes together with three metabolomics applications involving distinct biological annotation structures. Across both simulated and real datasets, incorporating external biological information consistently improves metabolite effect estimation. Gains are most pronounced when sample sizes are small and metabolite classes are informative, i.e. more homogenous within classes.